EGFR and cancer: For example, a computational platform called VirtualKinomeProfile has been used to profile compound-kinase interactions and predict the inhibitory activity of repurposed drugs, ultimately identifying 19 small-molecule inhibitors of epidermal growth factor receptor (EGFR), hematopoietic cell kinase (HCK), vascular endothelial growth factor receptor 1 (VEGFR1), and mitogen- and stress-activated kinase 1 (MSK1)—key kinases implicated in cancer progression [57].